Komori
General Meetings of Shareholders4884Kringle Pharma,Inc.Pharmaceuticals

Notice of Resolutions Adopted at the Extraordinary General Meeting of Shareholders

At the Extraordinary General Meeting of Shareholders, the proposal to reduce stated capital and capital reserve, transfer the resulting amount to other capital surplus, and apply the entire amount to offset the deficit in retained earnings brought forward was approved as proposed. The effective date is scheduled for 15 September 2026, subject to completion of creditor protection procedures.

Worth reading
87Important
Scored from 1 of 4 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1672709201
¥
Wording
Conditional
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Extraordinary General Meeting of Shareholders
2026
Aug 28
Date and time(start time: Not disclosed)
Matters for resolution1 item
  1. Reduction of the Amounts of Stated Capital and Capital Reserves and Disposition of Surplus

Shareholder Proposal

None (Not disclosed)

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingExtraordinary General Meeting of Shareholders
Date and time28 August 2026 (start time: Not disclosed)
Matters for resolutionReduction of the Amounts of Stated Capital and Capital Reserves and Disposition of Surplus
Shareholder ProposalNone (Not disclosed)
Items this document does not state (2)
Director nomineePercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To transfer the increase in other capital surplus to retained earnings brought forward and apply it to offset the deficit in retained earnings brought forward.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Resolutions Adopted at the Extraordinary General Meeting of Shareholders | Kringle Pharma,Inc. (4884) timely disclosure | Komori